A consortium of 5 European partners have been awarded €3 million grant funding by the European Innovation Council through its Fast Track to Innovation framework. The two-year project, Swirl SAFE infusion, will see Swedish company Tada Medical AB working with Irish companies Gasgon Medical and Remote Signals to develop their respective medical devices. This collaborative study will then trial the technologies in two European hospitals, Centro Hospitalar e Universitário de Coimbra, Portugal, and Parc Sanitari Sant Joan de Déu, Spain, ahead of a planned European launch.
The expected results of the project will determine if its technology can be used to improve delivery of IV drugs in hospital and homecare settings. Tada Medical AB and Gasgon Medical are developing devices to reduce the issues of IV dislodgement and Air-in-Line respectively, while Remote Signals will create a cloud-connected sensor device to remotely inform clinicians of performance of the infusion.
Tada Medical AB and Gasgon Medical are alumni of EIT Health, actively engaging with the supports of the organisation to advance their companies. Having met through the network after both receiving Headstart, they teamed up at matchmaking events to develop the Swirl project as a joint initiative. No strangers to success, both companies have been Catapult finalists, with Gasgon Medical achieving 2nd place overall in MedTech category in 2019. By sharing resources and connections they have leveraged the EIT Health network to source pan-European partners with same goals of improving healthcare.
First meeting of commercial partners in-person
It is amazing to meet your business connections in real life after a long time. The teams of 3 commercial partners involved in the FTI project i.e., Tada Medical, Gasgon Medical and Remote Signals were more than happy to finally meet in Ireland. It was great to have insightful discussions with the group on the SWIRL SAFE-Infusion project. A project collaboration that started over TEAMS calls and has shaped up so well in recent times.
Comments